Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A. Boorjian, Colin P. Dinney, Leonard G. Gomella et al.|The Lancet Oncology|2020Cited by 459
Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized StudyNeal D. Shore, Colin P. Dinney, Stephen A. Boorjian et al.|Journal of Clinical Oncology|2017Cited by 175